507 results on '"Diverio, D"'
Search Results
2. Spetta al giudice nazionale valutare la proporzionalità delle sanzioni previste dalla disciplina del distacco disapplicando all'occorrenza le disposizioni di legge attuative della direttiva
3. Incentivi fiscali alle aggregazioni aziendali e divieto di aiuti pubblici ai sensi del diritto europeo della concorrenza: c'è ancora spazio per un intervento autonomo dello Stato a sostegno dell'economia nazionale?
4. Regolamento (UE) 12 dicembre 2012, n. 1215/2012. Commento agli artt. 20-23
5. Molecular Biological Detection of Minimal Residual Disease in Acute Myeloid Leukemia
6. Polymerase Chain Reaction Approach for the Evaluation of Minimal Residual Disease in Acute Leukemia
7. Molecular Diagnosis and Monitoring of Acute Promyelocytic Leukemia: Updated Results of the Italian Gimema Group
8. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes
9. BCR-ABL1 GENE TRANSLOCATION MONITORING IN LONG-TERM SURVIVING CHRONIC MYELOID LEUKEMIA PATIENTS AFTER MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION: PH-P098
10. PLZF-mediated control on c-kit expression in CD34+ cells and early erythropoiesis
11. Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: focus on DNA repair genes
12. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations
13. Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): A comparison with NPMc+ AML
14. PLZF-mediated control on VLA-4 expression in normal and leukemic myeloid cells
15. Characterization of a recurrent translocation t(2;3)(p15–22;q26) occurring in acute myeloid leukaemia
16. Analysis of p73 expression pattern in acute myeloid leukemias: lack of ΔN-p73 expression is a frequent feature of acute promyelocytic leukemia
17. Interleukin-3 receptor in acute leukemia
18. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease
19. Hypermethylation of GpG islands in the promoter region of p15INK4b in acute promyelocytic leukemia represses p15INK4b expression and correlates with poor prognosis
20. C-fms expression correlates with monocytic differentiation in PML-RARα+ acute promyelocytic leukemia
21. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol
22. Expression pattern of HOXB6 homeobox gene in myelomonocytic differentiation and acute myeloid leukemia
23. Ear involvement in acute promyelocytic leukemia at relapse: a disease-associated ‘sanctuary’?
24. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts
25. Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patients
26. HLA class I in acute promyelocytic leukemia (APL): possible correlation with clinical outcome
27. Persistence of BCR-ABL1 gene signal in 10-year survivors of myeloablative allogeneic haematopoietic stem cell transplantation for chronic myeloid leukaemia: P722
28. Preliminary experience in external quality control of RT-PCR PML-RARα detection in promyelocytic leukemia
29. Evaluation of prospective real-time quantitative PCR monitoring for minimal residual disease to predict relapse and direct molecularly targeted therapy with arsenic trioxide in acute promyelocytic leukaemia: analysis of 407 patients, including results of the MRC AML1 5 trial: 162
30. Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status
31. Use of quantitative PCR approaches to predict relapse and direct molecularly targeted therapy with arsenic trioxide (ATO) in acute promyelocytic leukaemia (APL): 116
32. BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results
33. Multiple relapses and extramedullary localization with scalp and breast involvement in a case of acute promyelocytic leukaemia
34. Molecular Biological Detection of Minimal Residual Disease in Acute Myeloid Leukemia
35. DETECTION OF MINIMAL RESIDUAL DISEASE (MRD) IN APL BY "REAL-TIME" RT-PCR: ANALYSIS OF CASES ENTERED INTO THE MRC ATRA TRIAL
36. PS1172 DDPCR AT THE TIME OF TKI DISCONTINUATION IN CHRONIC PHASE CHRONIC MYELOID PATIENTS IS PREDICTIVE OF TREATMENT-FREE REMISSION OUTCOME
37. THERAPY OF MINIMAL DISEASE RECURRENCE IN ACUTE PROMYELOCYTIC LEUKEMIA
38. CLINICAL AND BIOLOGICAL RELEVANCE OF IMMUNOPHENOTYPE IN ACUTE PROMYELOCYTIC LEUKEMIA: A STUDY OF 196 CASES
39. HLA CLASS I AND SUSCEPTIBILITY TO ACUTE PROMYELOCYTIC LEUKEMIA
40. Detection of minimal residual disease (MRD) in APL by 'real-time' RT-PCR: Analysis of cases entered into the UK MRC ATRA trial
41. Managing Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. The Italian Experience
42. Erratum: Characterization of a recurrent translocation t(2;3)(p15–22;q26) occurring in acute myeloid leukemia
43. Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients
44. BCR-ABL1 GENE TRANSLOCATION MONITORING IN LONG-TERM SURVIVING CHRONIC MYELOID LEUKEMIA PATIENTS AFTER MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
45. LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN COMPLETE MOLECULAR RESPONSE WITH ALPHA-INTERFERON AFTER TREATMENT DISCONTINUATION
46. Primary Trombocythemia in Children and Adolescents Includes Different Subtypes Compared to Adult Essential Thrombocythemia
47. When can we safely talk about healing in chronic myeloid leukaemia patients after allogeneic haematopoietic stem cell transplant?
48. Discontinuation of Imatinib (IM) in pediatrica chronic myeloid leukemia (CML) patients with sustained complete molecular remission (CMR)
49. PERSISTENCE OF THE BCR/ABL GENE IN GREATER THAN 10-YEAR SURVIVORS OF MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA
50. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.